Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311169 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL3309411 | 0.78 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL6364221 | 0.78 | — | — | |
| SCHEMBL11572913 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL678952 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL28055180 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL27635464 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL6116212 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL72779 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2MLNR | |
| SCHEMBL1260399 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | SLC6A2 1860/4885SLC6A4 1700/4885SLC6A3 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.